
The Cribsiders
S5 Ep102: RSV Immunizations
Podcast summary created with Snipd AI
Quick takeaways
- Vaccination against RSV is available for both infants and adults, with Bayfortis recommended for infants and AretaSub and AbrezaSub suitable for adults, offering protection against RSV symptoms and reducing hospitalizations.
- RSV vaccination aims to prevent lower respiratory tract infections, reduce the burden of the disease, and may have the potential for broader coverage and expanding target populations in the future.
Deep dives
RSV Immunizations for Young and Old
RSV is a significant respiratory illness that affects both young infants and older adults. Vaccination against RSV can help prevent the disease and reduce its burden. Bayfortis (Nirsevumab) is a passive immunization option for babies that offers protection against RSV. For older individuals, there are two active immunization options: AretaSub and AbrezaSub vaccines. Both vaccines target the pre-fusion confirmation of the F protein of RSV and have demonstrated efficacy in reducing symptoms and hospitalizations related to RSV. The vaccines have different adjuvant options, and while they may cause some local and systemic side effects, the benefits of preventing RSV outweigh the risks. These vaccines serve not only to protect individuals but also to reduce the overall burden of RSV in the community. Pregnant women can receive the Pfizer vaccine to provide passive protection to their babies. Ongoing studies will further explore the effectiveness and long-term impact of RSV vaccines.